Amoxicillin + clavulanic acid

Essential medicine status

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.5. Antituberculosis medicines

EMLc | ATC codes: J01CR02

Indication	Multi-drug resistant Mycobacterium tuberculosis ICD11 code: MG52.00
INN	Amoxicillin + clavulanic acid
Medicine type	Chemical agent
Antibiotic groups	ACCESS
List type	Core
Additional notes	For use only in combination with meropenem or imipenem + cilastatin (EML). For use only in combination with meropenem (EMLc)
Formulations	**Oral > Liquid:** 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid (EMLc) **Oral > Solid > dispersible tablet:** 250 (as trihydrate) + 62.5 (as potassium salt) (EMLc) **Oral > Solid > tablet:** 500 mg (as trihydrate) + 125 mg (as potassium salt)
EML status history	First added in 2019 (TRS 1021) Changed in 2021 (TRS 1035) Changed in 2025 (TRS 1064)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Amoxicillin + clavulanic acid
DrugBank	Amoxicillin, Clavulanic acid (Clavulanate)

Summary of evidence and Expert Committee recommendations

The Expert Committee recommended the transfer of listings for medicines for multi-drug resistant tuberculosis from the complementary to the core list of the EML and EMLc. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of amoxicillin + clavulanic acid 250 mg + 62.5 mg dispersible tablets to the EMLc.